Download PDF
Thromb Haemost 2003; 90(06): 1179-1186
DOI: 10.1160/TH03-05-0305
Vascular Development and Vessel Remodelling
Schattauer GmbH

Accumulation of radiolabelled platelets and fibrin on the carotid artery of rabbits after angioplasty: effects of heparin and dipyridamole

Joanne van Ryn
1   Department of Drug Discovery Support, Boehringer Ingelheim, Biberach, Germany
,
Martin Lorenz
4   All For One Software AG, Oberessendorf, Germany
,
Herbert Merk
2   Medical Data Services, Boehringer Ingelheim, Biberach, Germany
,
Michael R. Buchanan
5   Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Canada
,
Wolfgang G. Eisert
3   R&D Coordination, Boehringer Ingelheim, Biberach, Germany
› Author AffiliationsFinancial support: This work was funded in part by the Heart and Stroke Foundation of Ontario.
Further Information

Publication History

Received 21 May 2003

Accepted after revision 30 July 2003

Publication Date:
05 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

We investigated the dynamic accumulation of platelets and fibrin after balloon injury of the carotid arteries in rabbits in vivo. In addition, effects of heparin and dipyridamole treatment were also tested. Autologous 99mTc-labelled platelet and 123I-labelled fibrin accumulation was measured at one minute intervals for 4 hours following balloon injury of the carotid artery. Platelet accumulation occurred rapidly, with a ~125% increase occurring within 30 min after injury. There was no further activity for up to 4 hours. This accumulation could be inhibited with an intravenous infusion of PGI2 (500 ng/kg/hr). Fibrin accumulation occurred slowly and continuously over the 4 hour measurement period. Injection of an anti-fibrin antibody inhibited fibrin accumulation. Heparin (25 U/kg/hr for 4 hrs) administration resulted in a significant 82 ± 19% and 68 ± 13% reduction in platelet and fibrin accumulation, respectively. This dose of heparin was associated with a 2-fold prolongation of the aPTT. Dipyridamole (0.45 mg/kg/hr for 4 hrs) resulted in a 46 ± 12% and 70 ± 25% reduction of platelet and fibrin accumulation, respectively. Thus, we demonstrated that the dynamics of platelet and fibrin accumulation following balloon injury in rabbits are very different. The vessel wall continues to be thrombogenic for fibrin up to 4 hours after injury even though platelet accumulation has ceased after one hour. We conclude that the local thrombotic events following balloon injury are complex and that not only platelets but also fibrin is important in regulating responses to injury.

Keywords

Animal models - platelet pharmacology - fibrin - vascular injury - dipyridamole
 

  • References

  • 1 Popma JJ, Ohman EM, Weitz J. et al. Antithrombotic therapy in patients undergoing percutaneous coronary intervention. Chest 2001; 119: 321S-36S.
    CrossrefPubMedGoogle Scholar
  • 2 Narins CR, Hillegass WB, Nelson CL. et al. Relation between activated clotting time during angioplasty and abrupt closure. Circulation 1996; 93: 667-71.
    CrossrefPubMedGoogle Scholar
  • 3 Gerns GAA, Stewart-Lee AL, Änggård EE. Arterial response to mechanical injury: balloon catheter de-endothelialization. Atherosclerosis 1992; 92: 89-104.
    CrossrefPubMedGoogle Scholar
  • 4 Virmani R, Farb A, Burke AP. Coronary angioplasty from the perspective of atherosclerotic plaque: Morphologic predictors of immediate success and restenosis. Am Heart J 1994; 127: 163-79.
    CrossrefPubMedGoogle Scholar
  • 5 Mintz GS, Pichard AD, Kent KM. et al. Axial plaque redistribution as a mechanism of percutaneous transluminal coronary angioplasty. Amer J Cardiol 1996; 77: 427-30.
    CrossrefPubMedGoogle Scholar
  • 6 De Feyter PJ, van den Brand M, Jaarman GJ. et al. Acute coronary artery occlusion during and after percutaneous transluminal coronary angioplasty. Circulation 1991; 83: 927-36.
    CrossrefPubMedGoogle Scholar
  • 7 Plante S, Laarman GJ, de Feyter P. et al. Acute complications of percutaneous transluminal coronary angioplasty for total occlusion. Am Heart J 1991; 121: 417-26.
    CrossrefPubMedGoogle Scholar
  • 8 Hirsh J, Anand SS, Halperin JL. et al. Guide to anticoagulant therapy: Heparin: A statement for healthcare professionals from the American Heart Association. Circulation 2001; 103: 2994-3018.
    CrossrefPubMedGoogle Scholar
  • 9 Gargan PE, Gaffney PJ, Pleasants JR. et al. A monoclonal antibody which recognises an epi-topic region unique to the intact fibrin polymeric structure. Fibrinolysis 1993; 7: 275-83.
    PubMedGoogle Scholar
  • 10 Regoeczi E. Fibrinogen catabolism: Kinetics of catabolism following sudden elevation of the pool with exogenous fibrinogen. Clin Sci 1970; 38: 111-21.
    CrossrefPubMedGoogle Scholar
  • 11 Greenwood FC, Hunter WM, Glovers JS. The preparation of 131I-labelled human growth hormone of high specific radioactivity. Biochem J 1963; 89: 114-21.
    CrossrefPubMedGoogle Scholar
  • 12 Becker W, Borst U, Krahe T. et al. Tc-99m-HMPAO labelled human platelets: in vitro and in vivo results. Eur J Nucl Med 1989; 15: 296-301.
    CrossrefPubMedGoogle Scholar
  • 13 Lorenz M, Van Ryn J, Merk H. et al. Portable gamma spectroscopy system for simultaneously monitoring radiotracers in vivo using CdTe and CdZnTe radiation detector probes. Nucl Instr and Meth in Phys Res 1994; A353: 448-52.
    CrossrefPubMedGoogle Scholar
  • 14 Proctor RR, Rappaport I S. The partial thromboplastin time with kaolin. Am J Clin Pathol 1961; 36: 212-18.
    CrossrefPubMedGoogle Scholar
  • 15 Bruning JL, Kintz BL. Computational Handbook of Statistics. Glenview, IL. Scott: Fores-man and Company; 1977
    Google Scholar
  • 16 Steele PM, Chesebro JH, Stanson AW. et al. Balloon Angioplasty. Natural history of the pathophysiological response to injury in a pig model. Circ Res 1985; 57: 105-112.
    CrossrefPubMedGoogle Scholar
  • 17 Groves HM, Kinlough-Rathbone RL, Richard-son M. et al. Platelet interaction with damaged rabbit aorta. Lab Invest 1979; 40: 194-200.
    PubMedGoogle Scholar
  • 18 Kelly AB, Marzec UM, Krupski W. et al. Hirudin interruption of heparin-resistant arterial thrombus formation in baboons. Blood 1991; 77: 1006-12.
    PubMedGoogle Scholar
  • 19 Heras M, Chesebro JH, Penny WJ. et al. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Circulation 1989; 79: 657-65.
    CrossrefPubMedGoogle Scholar
  • 20 Harker LA, Kelly AB, Hanson SR. Experimental arterial thrombosis in nonhuman primates.Circulation. 1991: 83suppl IV IV41-IV55.
    Google Scholar
  • 21 Richardson M, Hatton MWC, Buchanan MR. et al. Wound healing in the media of the nor-molipemic rabbit carotid artery injured by air drying or by balloon catheter de-endothelialization. Am J Pathol 1990; 137: 1453-65.
    PubMedGoogle Scholar
  • 22 Weksler BB, Marcus AJ, Jaffe EA. Synthesis of prostaglandin I2 (prostacyclin) by cultured human and bovine endothelial cells. Proc Natl Acad Sci USA 1997; 74: 3922-6.
    PubMedGoogle Scholar
  • 23 McAdam BF, Catella-Lawson F, Mardini IA. et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999; 96: 272-7.
    CrossrefPubMedGoogle Scholar
  • 24 Ofosu FA, Sie P, Modi G. et al. The inhibition of thrombin-dependent positive-feedback reactions is critical to the expression of the anticoagulant effect of heparin. Biochem J 1987; 243: 579-88.
    CrossrefPubMedGoogle Scholar
  • 25 Hatton MWC, Moar SL, Richardson M. Enhanced binding of fibrinogen by the subendothelium after treatment of the rabbit aorta with thrombin. J Lab Clin Med 1990; 115: 356-64.
    PubMedGoogle Scholar
  • 26 Patrono C, Coller B, Dalen JE. et al. Platelet-Active Drugs. Relationship among dose, effectiveness and side effects. Chest 2001; 119: 39S-63S.
    CrossrefPubMedGoogle Scholar
  • 27 Eisert WG. Dipyridamole. In: Platelets. A Michelson, ed. Academic Press, San Diego, 2002. In Press.
    PubMedGoogle Scholar
  • 28 Diener HC, Cuhna L, Forbes C. et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13.
    CrossrefPubMedGoogle Scholar
  • 29 Ahn HS, Crim W, Romano M. et al. Effects of selective inhibitors on cyclic nucleotide phosphodiesterase of rabbit aorta. Biochem Pharma-col 1989; 38: 3331-9.
    CrossrefPubMedGoogle Scholar
  • 30 Gillespie PG, Beavo JA. Inhibition and stimulation of photoreceptor phosphodiesterases by dipyridamole and M&B 22, 948. Mol Pharma-col 1989; 36: 773-81.
    PubMedGoogle Scholar
  • 31 Buchanan MR, Hirsh J. A comparison of the effects of aspirin and dipyridamole on platelet aggregation in vivo and ex vivo. Thromb Res 1978; 13: 517-29.
    CrossrefPubMedGoogle Scholar
  • 32 Gresele P, Zojy C, Deckmyn H. et al. Dipyridamole inhibits platelet aggregation in whole blood. Thromb Haemost 1983; 50: 852-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Neri Serneri GG, Masotti G, Poggesi L. et al. Enhanced prostacyclin production by dipyrida-mole in man. Eur J Clin Pharmacol 1981; 21: 9-15.
    PubMedGoogle Scholar
  • 34 Weber E, Haas TA, Muller TH. et al. Relationship between vessel wall 13-HODE synthesis and vessel wall thrombogenicity following injury: influence of salicylate and dipyridamole treatment. Thromb Res 1990; 57: 383-92.
    CrossrefPubMedGoogle Scholar